Objective:

To investigate the effects of GLP-1 receptor agonists (GLP-1RAs) on lung cancer outcomes in patients with non-small cell lung cancer (NSCLC), highlighting their potential role in enhancing current treatment options.

Key Findings:

• GLP-1RA use was associated with longer recurrence-free survival in surgical patients, suggesting a potential benefit in post-operative care.
• Concurrent use of GLP-1RA and immune checkpoint inhibitors improved overall and progression-free survival, indicating a synergistic effect.
• Preclinical models showed GLP-1RA reduced tumor burden in obese subjects but not in normal-weight subjects, raising questions about the mechanisms involved.

Interpretation:

GLP-1RAs may enhance the efficacy of immunotherapy and improve lung cancer outcomes, particularly in overweight or obese patients, suggesting a need for tailored treatment approaches.

Limitations:

• The study is retrospective and may have inherent biases, necessitating cautious interpretation of results.
• Benefits observed were limited to specific patient populations (overweight/obese), highlighting the need for broader studies.
• Further research is needed to confirm findings, understand mechanisms, and explore effects in diverse patient demographics.

Conclusion:

GLP-1RAs present a potential opportunity to improve NSCLC treatment outcomes, warranting further investigation to validate these findings and explore their clinical applications.